Terminated PHASE3 INTERVENTIONAL 2-arm NCT04369469

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Acute Lung Injury Acute Respiratory Distress Syndrome COVID-19 Severe Pneumonia Pneumonia, Viral

Interventions BSC Ravulizumab

Updated 17 times since 2020 Last updated: May 4, 2022 Started: May 10, 2020 Primary completion: Feb 8, 2021 Completion: Apr 8, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Met futility bar at interim analysis

Other terminated trials from Alexion Pharmaceuticals, Inc.

More terminations from Alexion Pharmaceuticals, Inc.

Other Acute Lung Injury trials with similar outcome

Browse all Acute Lung Injury trials

Listed as NCT04369469, this PHASE3 trial focuses on Acute Lung Injury and Acute Respiratory Distress Syndrome and remains terminated or withdrawn. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 17 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2023 — Jul 2024 [monthly]

Terminated PHASE3
Apr 2023 — Dec 2023 [monthly]

Terminated PHASE3

▶ Show 12 earlier versions

Jun 2022 — Apr 2023 [monthly]

Terminated PHASE3
Oct 2021 — Jun 2022 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Jun 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE3
Mar 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE3
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE3
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Barcelona, Spain , Birmingham, United Kingdom , Boston, United States , Bunkyō City, Japan , Charleston, United States , Chicago, United States , Créteil, France , Detroit, United States , Eau Claire, United States and 23 more locations